Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: A pilot study

Chest

Volumn 130, Issue 5, 2006, Pages 1471-1480

  Steiner, M Kathryn ^a,d   Preston, Ioana R ^a   Klinger, James R ^b   Criner, Gerard J ^c   Waxman, Aaron B ^d   Farber, Harrison W ^e   Hill, Nicholas S ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c TEMPLE UNIVERSITY HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BOSTON MEDICAL CENTER   (United States)

Author keywords

Bosentan; Epoprostenol; Pulmonary arterial hypertension; Transitions; Treprostinil

Indexed keywords

AMINOTRANSFERASE; BOSENTAN; CYCLOSPORIN A; GLIBENCLAMIDE; PROSTACYCLIN; UNIPROST;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DETERIORATION; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FATALITY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; JAW; LEG PAIN; LUNG ARTERY PRESSURE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PATIENT MONITORING; PATIENT SELECTION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SCORING SYSTEM; SIDE EFFECT; THORAX PAIN; WALKING; WITHDRAWAL SYNDROME;

EID: 33751253792     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.5.1471     Document Type: Article

References (19)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111-117
2. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-75
3. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159:1925-1932
4. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214-221
5. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302
6. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132:425-434
7. McLaughlin W, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477-1482
8. Vachiery JL, Hill N, Zwicke D, et al. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121:1561-1565
9. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172:1586-1589
10. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903
11. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 2003; 124:1612-1615
12. Suleman N, Frost AE. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 2004; 126:808-815
13. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161:487-492
14. American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117
15. Bossone E, Duong-Wagner TH, Paciocco G, et al. Echocardiographic features of primary pulmonary hypertension. J Am Soc Echocardiogr 1999; 12:655-662
16. Brecker SJ, Gibbs JS, Fox KM, et al. Comparison of Doppler derived haemodynamic variables and simultaneous high fidelity pressure measurements in severe pulmonary hypertension. Br Heart J 1994; 72:384-389
17. Hinderliter AL, Willis PWT, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension: Primary Pulmonary Hypertension Study Group. Circulation 1997; 95:1479-1486
18. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000; 6:453-458
19. Penning S, Robinson KD, Major CA, et al. A comparison of echocardiography and pulmonary artery catheterization for evaluation of pulmonary artery pressures in pregnant patients with suspected pulmonary hypertension. Am J Obstet Gynecol 2001; 184:1568-1570